Premium
Nesiritide during extracorporeal membrane oxygenation
Author(s) -
Smith Todd,
Rosen David A.,
Russo Pierantonio,
Berkenbosch John W.,
Gustafson Robert A.,
Siu Benjamin L.,
Rosen Kathleen R.,
Tobias Joseph D.
Publication year - 2005
Publication title -
pediatric anesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.704
H-Index - 82
eISSN - 1460-9592
pISSN - 1155-5645
DOI - 10.1111/j.1460-9592.2004.01398.x
Subject(s) - nesiritide , medicine , extracorporeal membrane oxygenation , extracorporeal , natriuretic peptide , heart failure , dosing , population , cardiology , anesthesia , environmental health
Summary Nesiritide is a recombinant formulation of B‐type natriuretic peptide (BNP). Preliminary experience in the adult population has shown nesiritide to be an effective agent in the treatment of decompensated congestive heart failure (CHF) in adults. Given its physiological effects, it may be an effective agent in other clinical scenarios. We report the use of nesiritide in two infants during extracorporeal membrane oxygenation (ECMO). In one patient, nesiritide in doses up to 0.09 μg·kg −1 ·min −1 were used to control mean arterial pressure while in the other patient, doses of 0.01–0.03 μg·kg −1 ·min −1 were used to augment urine output. The potential applications of nesiritide and dosing regimens for this agent in the ECMO population are discussed.